Cardiff Oncology Reports Second Quarter 2023 Results and Pro

/PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug...

Related Keywords

Richa Kumari , James Levine , Mark Erlander , Kiki Patel , Pfizer , Nasdaq , Gilmartin Group , Exchange Commission , Pfizer Global Product Development , Dana Farber Cancer Institute , Prnewswire Cardiff Oncology Inc , Cardiff Oncology Inc , Medicine Team Group Lead For Breast Cancer , Taft Communications , Cardiff Oncology , Chief Executive Officer , Pfizer Ignite , Vice President , Medicine Team Group Lead , Breast Cancer , Colorectal Cancer , Scientific Advisory Board , Private Securities Litigation Reform Act , Oncology Contact , Financial Officer , Months Ended June , Nc , Health Care Amp Hospitals , Otc , Mallcap , Medical Pharmaceuticals , Biotechnology , Earnings ,